Micro-mobile Foot Compression Device to Improve Motor-function in People With Diabetes and Loss of Protective Sensation
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Diabetes
- Sponsor
- Baylor College of Medicine
- Enrollment
- 30
- Locations
- 1
- Primary Endpoint
- Change in Balance From Baseline to 4 Weeks
- Status
- Completed
- Last Updated
- 4 years ago
Overview
Brief Summary
Diabetic foot ulceration (DFU) is a common and largely preventable complication. While most of these ulcers can be treated successfully, some will persist and become infected. Ultimately, nearly one fifth of patients with infected lower-extremity diabetic ulcers will require amputation of the affected limb.Prevention by identifying people at higher risk is the key for better clinical management of such patients. It is not uncommon for patients suffering from diabetes to have concomitant lower extremity edema or even venous insufficiency and they subsequently may benefit from graduated compression. However, because of the common association of peripheral arterial disease (PAD) in patients with diabetes, most clinicians are reluctant to apply compressive dressings in fear of exacerbating the symptoms of PAD and the possible resulting gangrene.
A novel micro-mobile foot compression device named Footbeat (AVEX, Inc.) offers alternative means providing lower extremity compression. This device is portable and can be used in a standard diabetic shoes on daily basis, which in turn may improve venous blood and relief from concomitant lower extremity edema. In addition, potential improvement in lower extremity blood flow in response to regular foot compression, could improve balance, gait, skin perfusion, plantar sensation, and overall daily physical activities (e.g. number of taken steps per day, duration of standing, etc).
The purpose of this study is to conduct an observational study with N=30 ambulatory patients with diabetes and loss of protective sensation to assess whether this micro-mobile foot compression device can help improving motor function, lower extremity perfusion, and vascular health.
Investigators
Bijan Najafi, PhD
Professor of Surgery
Baylor College of Medicine
Eligibility Criteria
Inclusion Criteria
- •Male or female , age 18 or older with the ability and willingness to provide Informed consent
- •Patient is willing to participate in all procedures and follow up evaluations necessary to complete the study
- •History of type 2 diabetes confirmed by patient's physician.
- •History of peripheral neurpathy .
Exclusion Criteria
- •Patients with severe peripheral vascular disease (ankle-brachial systolic pressure index (ABI) \<0.5 or ABI\>1.30)
- •Patients with active wound infection, or untreated osteomyelitis
- •Patients with major foot deformities (e.g. Charcot Foot) or major amputation (e.g. above ankle)
- •Unamulatory of those who are unable to independently walk with or without walking assistance, a distance of 40 feet.
- •Patients who are unable or unwilling to participate in all procedures and follow up evaluations
- •Patients currently on immunosuppressive drugs.
- •Pregnant or breast feeding ladies.
Outcomes
Primary Outcomes
Change in Balance From Baseline to 4 Weeks
Time Frame: baseline and 4 weeks.
Balance will be quantified by measuring body sway in medial-lateral direction using a validated wearable sensors technology (Balansens, Biosensics LLC) and body sway change after 4-weeks of daily use of AVEX Footbeat will be assessed compare to baseline. Th unit of measurement is cm.
Change in Skin Perfusion From Baseline to 4 Weeks
Time Frame: Baseline and 4 weeks
Skin perfusion was quantified using Skin Perfusion Pressure Test (SPP) at the lower extremities at baseline and at 4-week (end point). The measurement of SPP was done using a device called Sensilase PAD-IQ (VASAMED). The unit of measurement is mmHg.
Secondary Outcomes
- Change in Lower Extremity Edema From Baseline to 4 Weeks(Baseline and 4 weeks)
- Change in Stride Velocity From Baseline to 4-week(Baseline to 4 weeks)
- Change in Plantar Sensation From Baseline to 4-week(Baseline to 4 weeks)